Inflammation Biomarkers and Risk of All-Cause Mortality in the Reasons for Geographic and Racial Differences in Stroke Cohort

被引:45
作者
Kabagambe, Edmond K. [1 ]
Judd, Suzanne E. [2 ]
Howard, Virginia J. [1 ]
Zakai, Neil A. [3 ,4 ]
Jenny, Nancy S. [4 ]
Hsieh, Matthew [5 ]
Warnock, David G. [6 ]
Cushman, Mary [3 ,4 ]
机构
[1] Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA
[2] Univ Alabama, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA
[3] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA
[4] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA
[5] NIDDK, Mol & Clin Hematol Branch, Bethesda, MD USA
[6] Univ Alabama, Div Nephrol, Dept Med, Sch Med, Birmingham, AL 35294 USA
关键词
biological markers; cohort studies; C-reactive protein; inflammation; leukocytes; mortality; prospective studies; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; LEUKOCYTE COUNT; CARDIOVASCULAR-HEALTH; POSTMENOPAUSAL WOMEN; ASSOCIATION; MEN; US; PREDICTORS; ALBUMIN;
D O I
10.1093/aje/kwr085
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Inflammation biomarkers, including higher high-sensitivity C-reactive protein (hsCRP) levels, higher white blood cell (WBC) counts, and lower serum albumin levels, are associated with an increased risk of all-cause mortality. Many studies have examined these biomarkers individually, but less is known about their joint association with mortality. hsCRP, WBC count, and serum albumin were measured at baseline in the Reasons for Geographic and Racial Differences in Stroke Study cohort members, who were enrolled in 2003-2007. Over 4.5 years, there were 1,062 deaths in 17,845 participants. High-risk categories were defined as hsCRP or WBC levels above the 75th percentile (5.1 mg/L and 6.9 x 10(9) cells/L, respectively) and albumin levels below the 25th percentile (4.00 g/dL). The authors derived 4 groups that corresponded to 0 (n = 8,341), 1 (n = 6,277), 2 (n = 2,635), or 3 (n = 592) biomarkers in the high-risk category. After adjustment for age, sex, waist circumference, race, region, smoking, alcohol use, income, educational level, physical activity frequency, and medical history and compared with those with no biomarkers in the high-risk category, the hazard ratios for all-cause mortality for 1, 2, and 3 biomarkers in the high-risk category were 1.56 (95% confidence interval: 1.33, 1.82), 2.19 (95% confidence interval: 1.84, 2.62), and 2.96 (95% confidence interval: 2.30, 3.80), respectively (P(trend) < 0.0001). Adding the 3 inflammation biomarkers to a fully adjusted model improved risk discrimination by 23.7% (95% confidence interval: 9.3, 39.9). Measurement of more than 1 biomarker is more useful in risk prediction than single biomarkers.
引用
收藏
页码:284 / 292
页数:9
相关论文
共 24 条
[11]   Inflammation biomarkers and near-term death in older men [J].
Jenny, Nancy Swords ;
Yanez, N. David ;
Psaty, Bruce M. ;
Kuller, Lewis H. ;
Hirsch, Calvin H. ;
Tracy, Russell P. .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2007, 165 (06) :684-695
[12]   Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment [J].
Joshi, Parag H. ;
Jacobson, Terry A. .
CURRENT ATHEROSCLEROSIS REPORTS, 2010, 12 (01) :34-42
[13]   C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis [J].
Kaptoge, Stephen ;
Di Angelantonio, Emanuele ;
Lowe, Gordon ;
Pepys, Mark B. ;
Thompson, Simon G. ;
Collins, Rory ;
Danesh, John ;
Tipping, R. W. ;
Ford, C. E. ;
Pressel, S. L. ;
Walldius, G. ;
Jungner, I. ;
Folsom, A. R. ;
Chambless, L. ;
Ballantyne, C. M. ;
Panagiotakos, D. ;
Pitsavos, C. ;
Chrysohoou, C. ;
Stefanadis, C. ;
Knuiman, M. W. ;
Goldbourt, U. ;
Benderly, M. ;
Tanne, D. ;
Whincup, P. ;
Wannamethee, S. G. ;
Morris, R. W. ;
Kiechl, S. ;
Willeit, J. ;
Mayr, A. ;
Schett, G. ;
Wald, N. ;
Ebrahim, S. ;
Lawlor, D. ;
Yarnell, J. ;
Gallacher, J. ;
Casiglia, E. ;
Tikhonoff, V. ;
Nietert, P. J. ;
Sutherland, S. E. ;
Bachman, D. L. ;
Keil, J. E. ;
Cushman, M. ;
Psaty, B. M. ;
Tracy, R. ;
Tybjaerg-Hansen, A. ;
Nordestgaard, B. G. ;
Zacho, J. ;
Frikke-Schmidt, R. ;
Giampaoli, S. ;
Palmieri, L. .
LANCET, 2010, 375 (9709) :132-140
[14]   Gender and C-reactive protein: Data from the Multiethnic Study of Atherosclerosis (MESA) cohort [J].
Lakoski, Susan G. ;
Cushman, Mary ;
Criqui, Michael ;
Rundek, Tatjana ;
Blumenthal, Roger S. ;
D'Agostino, Ralph B., Jr. ;
Herrington, David M. .
AMERICAN HEART JOURNAL, 2006, 152 (03) :593-598
[15]   A prospective study of inflammatory Cytokines and diabetes Mellitus in a multiethnic cohort of postmenopausal women [J].
Liu, Simin ;
Tinker, Lesley ;
Song, Yiqing ;
Rifai, Nader ;
Bonds, Denise E. ;
Cook, Nancy R. ;
Heiss, Gerardo ;
Howard, Barbara V. ;
Hotamisligil, Gokhan S. ;
Hu, Frank B. ;
Kuller, Lewis H. ;
Manson, JoAnn E. .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (15) :1676-1685
[16]   Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women [J].
Margolis, KL ;
Manson, JE ;
Greenland, P ;
Rodabough, RJ ;
Bray, PF ;
Safford, M ;
Grimm, RH ;
Howard, BV ;
Assaf, AR ;
Prentice, R .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (05) :500-508
[17]   Justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin (JUPITER) - Can C-reactive protein be used to target statin therapy in primary prevention? [J].
Mora, S ;
Ridker, PM .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (2A) :33A-41A
[18]   Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond [J].
Pencina, Michael J. ;
D'Agostino, Ralph B., Sr. ;
D'Agostino, Ralph B., Jr. ;
Vasan, Ramachandran S. .
STATISTICS IN MEDICINE, 2008, 27 (02) :157-172
[19]   Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes Results From PROVE IT-TIMI 22 [J].
Ray, Kausik K. ;
Cannon, Christopher P. ;
Cairns, Richard ;
Morrow, David A. ;
Ridker, Paul M. ;
Braunwald, Eugene .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (03) :424-D6
[20]   Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial [J].
Ridker, Paul M. ;
Danielson, Eleanor ;
Fonseca, Francisco A. H. ;
Genest, Jacques ;
Gotto, Antonio M., Jr. ;
Kastelein, John J. P. ;
Koenig, Wolfgang ;
Libby, Peter ;
Lorenzatti, Alberto J. ;
MacFadyen, Jean G. ;
Nordestgaard, Borge G. ;
Shepherd, James ;
Willerson, James T. ;
Glynn, Robert J. .
LANCET, 2009, 373 (9670) :1175-1182